Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

608 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association between treatment and improvements in overall survival of patients with advanced/metastatic non-small cell lung cancer since 2011: A study in the United States, Canada, and Germany using retrospective real-world databases.
Griesinger F, Ramagopalan S, Cheung WY, Wilke T, Mueller S, Gupta A, O'Sullivan DE, Arora P, Brenner DR, Froelich C, Inskip J, Maywald U, Subbiah V. Griesinger F, et al. Among authors: subbiah v. Cancer. 2024 Feb 15;130(4):530-540. doi: 10.1002/cncr.35094. Epub 2023 Nov 7. Cancer. 2024. PMID: 37933916
Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience.
Wang Z, Shi N, Naing A, Janku F, Subbiah V, Araujo DM, Patel SR, Ludwig JA, Ramondetta LM, Levenback CF, Ramirez PT, Piha-Paul SA, Hong D, Karp DD, Tsimberidou AM, Meric-Bernstam F, Fu S. Wang Z, et al. Among authors: subbiah v. Cancer Med. 2016 Dec;5(12):3437-3444. doi: 10.1002/cam4.956. Epub 2016 Nov 23. Cancer Med. 2016. PMID: 27882721 Free PMC article.
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.
Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Maymani H, et al. Among authors: subbiah v. Lung Cancer. 2018 Jun;120:137-141. doi: 10.1016/j.lungcan.2018.03.020. Epub 2018 Apr 11. Lung Cancer. 2018. PMID: 29748008 Free PMC article.
Assessment of tumour-agnostic therapies in basket trials.
Popat S, Ramagopalan SV, Ray J, Roze S, Subbiah V. Popat S, et al. Among authors: subbiah v. Lancet Oncol. 2022 Jan;23(1):e7. doi: 10.1016/S1470-2045(21)00714-2. Lancet Oncol. 2022. PMID: 34973234 No abstract available.
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik CS, Tan DSW, Lee DH, Misch D, Garralda E, Kim DW, van der Wekken AJ, Gainor JF, Paz-Ares L, Liu SV, Kalemkerian GP, Houvras Y, Bowles DW, Mansfield AS, Lin JJ, Smoljanovic V, Rahman A, Kong S, Zalutskaya A, Louie-Gao M, Boral AL, Mazières J. Griesinger F, et al. Among authors: subbiah v. Ann Oncol. 2022 Nov;33(11):1168-1178. doi: 10.1016/j.annonc.2022.08.002. Epub 2022 Aug 13. Ann Oncol. 2022. PMID: 35973665 Free article. Clinical Trial.
608 results